Ion exchange chromatography method for detecting charge heterogeneity of IgG4 monoclonal antibodies
By using gradient eluent and buffer solution on strong cation chromatography columns, the problem of charge heterogeneity detection of IgG4 monoclonal antibodies is solved, efficient separation and accurate detection of Dupilumab and its biosimilars are achieved, and the product is improved Stability and accuracy of quality monitoring.
Patent Information
- Application Number
- CN202110997966.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-08-27
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-08-27
AI Technical Summary
The prior art is difficult to effectively isolate and detect charge heterogeneity of IgG4 type monoclonal antibodies, especially Dupilumab and its biosimilars, resulting in insufficient separation effect and stability.
A strong cation chromatography column with sulfonic acid functional groups combined with gradient eluent, using MES salt buffer solution and acetate buffer solution as mobile phase, combined with an appropriate proportion of acetonitrile and salt gradient, pH gradient control is carried out to achieve the IgG4 single type Efficient separation of acidic, neutral and alkali-charged isomers of cloned antibodies.
The high resolution, repeatability and accuracy of IgG4 monoclonal antibodies are achieved, and the charge isomers of Dupilumab and its biosimilars can be effectively detected, improving the monitoring ability of product quality attributes.
Smart Images

Figure CN115728433B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biopharmaceuticals and relates to an ion exchange chromatography detection method for charge heterogeneity of IgG4 type monoclonal antibodies. Background Art
[0002] As a targeted biological therapeutic drug, therapeutic monoclonal antibody drugs have become a hot spot for pharmaceutical companies to develop since they were approved by the FDA for marketing in 1986. Dupilumab monoclonal antibody is the first fully humanized IgG4 monoclonal antibody approved by the FDA for the treatment of moderate to severe atopic dermatitis. It inhibits the signal transduction of IL-4 and IL-13 by binding to the IL-4Rα subunit. Monoclonal antibodies have a molecular weight of about 150 kDa and are expressed in eukaryotic cells. During the biosynthesis, fermentation culture, purification and preparation of antibody molecules in cells, various post-translational modifications will occur, including oxidation, deamidation, heavy chain C-terminal lysine residues, isomerization and glycosylation. In addition, the combined factors of antibody molecule fragments and aggregates and other size variants lead to differences in the charge carried by antibody molecules, which ultimately present the characteristics of "heterogeneity", called charge isomers. The charge heterogeneity of antibody molecules is closely related to their stability and biological activity, and directly affects the stability of the product production process. Therefore, as a key quality attribute (CQA) of a product, it has received close attention in the development and production of antibody drugs.
[0003] The methods currently used to evaluate the charge heterogeneity of monoclonal antibodies include plate isoelectric focusing (IEF), capillary isoelectric focusing (CIEF), ion exchange chromatography (IEX), etc. Isoelectric focusing (IEF / CIEF) separates charge isomers based on the difference in isoelectric point of antibody molecules. The detection result of IEF is a gel band. At present, it is not possible to accurately quantify and analyze each charge isomer. Although CIEF can achieve accurate quantification, separation based on isoelectric point differences, and monitoring of modifications that cause isoelectric point changes, such as incomplete terminal lysine removal, it cannot monitor modifications that do not cause isoelectric point changes, such as oxidative modifications. In addition, the sample pretreatment of isoelectric focusing is complex, involving steps such as sample desalting, and is time-consuming. Ion exchange chromatography separates charge isomers based on the difference in antibody surface charge, and can comprehensively monitor all modification changes that cause heterogeneity. It does not require sample pretreatment, is simple to operate, and has higher sensitivity.
[0004] Currently, the most approved monoclonal antibodies belong to the IgG1 type, and the relevant research and analysis technologies are relatively mature. The existing technologies mainly focus on the analysis and detection of IgG1 type antibodies. In general, the analysis of charge isomers usually uses salt ion gradient-mediated weak cation chromatography, which can achieve better separation effects and meet the needs of process development and product quality assessment. However, there are fewer research reports on IgG2 and IgG4 ion exchange chromatography methods. There are great difficulties in the development of ion exchange chromatography detection methods for these two types of antibodies, and IgG4 monoclonal antibodies are more hydrophobic. Currently, there is no detection method for the charge heterogeneity of IgG4 monoclonal antibodies and their biosimilars with better separation effects and stability.
[0005] The article by Dai Zhenyu et al. (“High-resolution separation of monoclonal antibody sialylated isomers by pH gradient ion exchange chromatography”) discloses that strong cation exchange chromatography based on pH gradient on ProPac SCX-10 column can be used for high-resolution separation of monoclonal antibody sialylated isomers. However, this method has the defect of not being able to achieve good separation of acidic, neutral and basic isomers for charge heterogeneity analysis of IgG4 monoclonal antibodies, and it adopts the pH gradient separation principle.
[0006] Patent application CN109946410A discloses an ion exchange chromatography detection method using a weak cation chromatography column, specifically Propac WCX-10, to analyze the charge heterogeneity of monoclonal antibodies. However, this method cannot separate and detect the charge isomers of IgG4 monoclonal antibodies.
[0007] Therefore, it is necessary to develop a method for detecting the charge heterogeneity of IgG4 monoclonal antibodies with better separation effect and stability. Summary of the invention
[0008] In view of the above technical status, the purpose of the present invention is to provide a cation exchange chromatography detection method for charge heterogeneity analysis of IgG4 monoclonal antibodies, especially Dupilumab monoclonal antibodies and their biosimilars, which has good separation, high specificity, repeatability and accuracy. The detection method of the present invention includes the following:
[0009] The present invention provides an ion exchange chromatography detection method for monoclonal antibody charge heterogeneity, wherein the monoclonal antibody is an IgG4 type monoclonal antibody, and the detection conditions include: using a strong cationic chromatographic column with a sulfonic acid functional group, performing gradient elution with mobile phase A and mobile phase B,
[0010] Wherein, the mobile phase A is an ampholyte and its salt buffer solution, preferably MES (2-morpholineethanesulfonic acid) and its salt buffer solution, phosphoric acid and its salt buffer solution or acetic acid and its salt buffer solution, or a combination thereof;
[0011] The mobile phase B is an ampholyte and a salt buffer solution thereof, preferably MES (2-morpholineethanesulfonic acid) and a salt buffer solution thereof, phosphoric acid and a salt buffer solution thereof, or acetic acid and a salt buffer solution thereof, or a combination thereof;
[0012] The salt is a sodium salt or a potassium salt.
[0013] In the method of the present invention, as one of the embodiments, the strong cation chromatography column is YMC BioPro IEXSF or Thermo MAbPac SCX-10.
[0014] In the method of the present invention, as one of the embodiments, the method further comprises: the mobile phase A or the mobile phase B contains 0-10% by volume of acetonitrile, isopropanol, ethanol or methanol.
[0015] In the method of the present invention, as one of the embodiments, the method further comprises: the mobile phase A or the mobile phase B contains 5% by volume of acetonitrile, isopropanol, ethanol or methanol.
[0016] In the method of the present invention, as one of the embodiments, the method further comprises: the mobile phase A or the mobile phase B contains 5% by volume of acetonitrile.
[0017] In the method of the present invention, as one of the embodiments, the mobile phase A has a pH of 5.7-6.2, preferably a pH of 5.8-6.1, and optimally a pH of 6.0.
[0018] In the method of the present invention, as one of the embodiments, the mobile phase A is 10-50 mM MES and its salt buffer solution added with 5% volume of acetonitrile, preferably 20-50 mM, more preferably 30 mM MES and its salt buffer solution added with 5% volume of acetonitrile; as one of the embodiments, the mobile phase A is preferably 30 mM MES, pH 6.0, 5% volume of acetonitrile.
[0019] In the method of the present invention, as one of the embodiments, the mobile phase B is based on the mobile phase A as a base solution, and a 0.1M-1M sodium salt or potassium salt solution is added, preferably a 0.5M sodium chloride or potassium chloride solution is added.
[0020] In the method of the present invention, as one of the embodiments, the mobile phase B is: 30mM MES, 0.5M NaCl, pH6.0, 5% acetonitrile.
[0021] In the method of the present invention, as one of the embodiments, the method further comprises a mobile phase flow rate of 0.2-1.5 mL / min, preferably 0.4-0.6 mL / min, and further preferably 0.4 mL / min.
[0022] In the method of the present invention, as one of the embodiments, the method further comprises an elution gradient of:
[0023] Time / min Mobile phase A Mobile phase B 0min 93 7 2min 93 7 57min 82 18 59min 40 60 .
[0024] In the method of the present invention, as one of the embodiments, the method further comprises that the chromatographic column temperature during detection is 20-50°C, preferably 40°C.
[0025] In the method of the present invention, as one of the embodiments, the method further comprises using an ultraviolet detector with a detection wavelength of 280 nm and an injection volume of 5-100 μg, preferably 25-75 μg.
[0026] In the method of the present invention, as one of the embodiments, the method further includes processing the test sample: taking IgG4 monoclonal antibodies and biosimilars thereof, adding ultrapure water, mixing, and obtaining a test sample with a concentration of 2.5 mg / mL.
[0027] In the method of the present invention, as one of the embodiments, the IgG4 monoclonal antibody is Dupilumab and its biosimilars, or Nivolumab and its biosimilars.
[0028] In the method of the present invention, as one of the embodiments, 5 μL of Dupilumab is taken, 295 μL of ultrapure water is added, and the mixture is mixed to obtain a sample to be tested with a concentration of 2.5 mg / mL.
[0029] In the method of the present invention, as one of the embodiments, 25 μL of Nivolumab is taken, added to 75 μL of ultrapure water, mixed, and prepared to obtain a 2.5 mg / mL test sample.
[0030] In the method of the present invention, as one of the embodiments, the method further comprises: the efficient detection method of charge heterogeneity of Dupilumab or Nivolumab monoclonal antibody and its biosimilars comprises the following detection conditions:
[0031] Chromatographic column: YMC BioPro IEX SF or Thermo MAbPac SCX-10
[0032] Mobile phase: A-30 mM MES, pH 6.0, 5% acetonitrile;
[0033] B-30 mM MES, 0.5 M NaCl, pH 6.0, 5% acetonitrile
[0034] Column temperature: 40°C
[0035] Detection wavelength: 280nm
[0036] Injection volume: 25 μg
[0037] Flow rate: 0.4mL / min
[0038] Mobile phase gradient:
[0039] Time / min Mobile phase A Mobile phase B 0min 93 7 2min 93 7 57min 82 18 59min 40 60
[0040] In the method of the present invention, as one of the embodiments, the method comprises:
[0041] Preparation of the test sample: Take Dupilumab or Nivolumab, add ultrapure water, mix well, and obtain a test sample with a concentration of 2.5 mg / mL.
[0042] definition
[0043] In the present invention, "biosimilars" are also called "biosimilar drugs". In the "Technical Guidelines for Pre-evaluation of Biosimilar Drug Research and Development", it is clearly stated that "biosimilar drugs" refer to therapeutic biological products that are similar to the reference drugs that have been approved for registration in terms of quality, safety and effectiveness. In principle, the amino acid sequence of biosimilar drug candidates should be the same as the reference drug. In the present invention, generic drugs made using the sequence of Dupilumab or Nivolumab can be called biosimilars of Dupilumab or Nivolumab. The sample to be tested targeted by the present invention is a solution containing components with the same sequence or site mutations as Dupilumab or Nivolumab antibodies, including Dupilumab or Nivolumab and their biosimilars.
[0044] Compared with the prior art, the present invention has the following advantages and effects: the invention provides an ion exchange chromatography detection method for charge heterogeneity analysis of IgG4 monoclonal antibodies, especially Dupilumab and its biosimilars. Different from the traditional method of using a weak cation chromatographic column to analyze the charge heterogeneity of monoclonal antibodies, the present method uses a strong cation chromatographic column with a sulfonic acid group as a functional group in combination with a certain proportion of organic reagents added to the mobile phase to obtain a separation effect that is better than that of a variety of weak cation chromatographic columns. The method can effectively separate the acidic, neutral and basic charge isomers of IgG4 monoclonal antibodies, especially Dupilumab and its biosimilars, and has the advantages of high separation, good repeatability, high accuracy, good specificity, simple and fast operation, etc. In addition, the method has strong versatility and the separation effect of Nivolumab, which is also of IgG4 type, is better than that of a weak cation chromatographic column.
[0045] Therefore, the detection method of the present invention successfully realizes the effective detection of the charge isomers of IgG4 monoclonal antibodies, especially Dupilumab monoclonal antibodies and their biosimilars, so that the quality attributes of IgG4 monoclonal antibodies, especially Dupilumab monoclonal antibodies and their biosimilars products can be detected. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1 is a typical distribution diagram of acidic, neutral and basic charge isomers of Dupilumab antibody obtained under the detection conditions in Example 1;
[0047] Figure 2 is the distribution diagram of acidic, neutral and basic charge isomers of Dupilumab antibody obtained on Thermo propac Elite WCX under the detection conditions in Example 2;
[0048] Figure 3 is the distribution diagram of acidic, neutral and basic charge isomers of Dupilumab antibody obtained on Thermo propac WCX-10 under the detection conditions in Example 2;
[0049] Figure 4 is the distribution diagram of acidic, neutral and basic charge isomers of Dupilumab antibody obtained on Thermo MAbPac SCX-10 under the detection conditions in Example 3;
[0050] Figure 5 The figure is a diagram showing the separation effect of acidic, neutral and basic charge isomers of Dupilumab antibody measured under the mobile phase conditions of pH 5.8, 6.0 and 6.1 in Example 4;
[0051] Figure 61 is a graph showing the separation effect of acidic, neutral and basic charge isomers of Dupilumab antibody measured at a concentration of 20 mM and 50 mM using the mobile phase MES in Example 5;
[0052] Figure 7 This is a diagram showing the separation of acidic, neutral and basic charge isomers of Dupilumab antibody measured at flow rates of 0.4 and 0.6 mL / min in Example 6;
[0053] Figure 8 This is a diagram showing the separation of acidic, neutral and basic charge isomers of Dupilumab antibody measured under the conditions of salt ion gradients of 1.5, 1.0, 0.8 and 0.6 mM / min in Example 7;
[0054] Fig. 9 This is a graph showing the separation of acidic, neutral and basic charge isomers of Dupilumab antibody measured at 35, 37, 40 and 45° C. under the conditions of chromatographic column temperature in Example 8;
[0055] Fig.10 is a graph showing the separation of acidic, neutral and basic charge isomers of Dupilumab antibody after adding 0%, 2% and 5% acetonitrile by volume to the mobile phase in Example 9;
[0056] Fig.11 is a distribution diagram of acidic, neutral and basic charge isomers of Dupilumab antibody before and after carboxypeptidase B cleavage in Example 11;
[0057] Fig.12 is a linear regression line graph of the detection method of the present invention in Example 12;
[0058] Fig.13 The acidic, neutral and basic charge isomer distribution diagrams of Nivolumab monoclonal antibody detected under the detection conditions in Example 14;
[0059] Fig.14 This is the distribution diagram of acidic, neutral and basic charge isomers of Nivolumab monoclonal antibody detected by Thermofisher's weak cation chromatography column in Example 14. DETAILED DESCRIPTION
[0060] The present invention is further described in detail below in conjunction with examples, but the embodiments of the present invention are not limited thereto.
[0061] Instruments and reagents
[0062] Table 1
[0063]
[0064]
[0065] Example 1
[0066] This example is a detection experiment of the charge isomers of Dupilumab antibody using a YMC BioPro IEX SF column. The experimental process is as follows:
[0067] (1) Preparation of test sample 1 (also referred to as "treatment of test sample 1"): Take 5 μL of Dupilumab monoclonal antibody (lot number 9L003K), add 295 μL of ultrapure water, mix well, and obtain a test sample with a concentration of 2.5 mg / mL.
[0068] (2) Determine the chromatographic conditions: The chromatographic conditions for detection are shown in Table 2.
[0069] Table 2
[0070]
[0071] Test results such as Figure 1 As shown, the acidic charge isomers, neutral charge isomers and basic charge isomers of Dupilumab monoclonal antibody can be effectively separated using the above detection conditions.
[0072] Example 2
[0073] This example is compared with Example 1 to detect the separation effect of Dupilumab on a weak cation chromatographic column under the same mobile phase conditions.
[0074] (1) Treatment of the test sample: same as in Example 1.
[0075] (2) The chromatographic conditions for detection are shown in Table 3
[0076] Table 3
[0077]
[0078] Test results such as Figure 2 As shown, the Dupilumab antibody has only a small amount of separation of the acid peak on the Thermo propac Elite WCX, and no separation effect on the base peak.
[0079] In addition, Dupilumab antibody was separated on a Thermo propac WCX-10 weak cation column using the same mobile phase and salt ion gradient. Figure 3As shown, this chromatographic column is widely used in the evaluation of charge heterogeneity of IgG1 antibodies, but has no separation effect on the acidic, neutral and basic charge isomers of Dupilumab antibodies. The above comparative examples fully illustrate that the strong cation chromatographic column has great superiority in the charge heterogeneity analysis of Dupilumab antibodies.
[0080] Example 3
[0081] This example studies the separation effect of different strong cation chromatographic columns on the charge isomers of Dupilumab.
[0082] The sample treatment was the same as in Example 1, and the chromatographic column was Thermo MAbPac SCX-10. Except for the chromatographic column, other detection conditions were the same as in Example 1.
[0083] Test results such as Figure 4 As shown, under the same other detection conditions, the separation effect of the Thermo MAbPac SCX-10 strong cation chromatography column on the acidic, neutral and basic charge isomers of Dupilumab is equivalent to that of Example 1.
[0084] Example 4
[0085] This example studies the effect of different mobile phase pH values on the separation of Dupilumab charge isomers.
[0086] The sample treatment was the same as in Example 1, and the chromatographic detection conditions were as shown in Table 4:
[0087] Table 4
[0088]
[0089]
[0090] Test results such as Figure 5 As shown, when the mobile phase pH value is 5.8, 6.0 and 6.1, the detection conditions have similar separation effects on the acidic, neutral and basic isomers of Dupilumab antibody and can all meet the separation requirements. From the shape of each peak, pH 6.0 is the optimal pH value.
[0091] Example 5
[0092] This example studies the effect of different MES concentrations on the separation of Dupilumab charge isomers.
[0093] The treatment of the test sample was the same as in Example 1. The only difference between the chromatographic detection conditions and those in Example 1 was the concentration of MES. The detection conditions of 20 and 50 mM MES were investigated.
[0094] Test results such as Figure 6 As shown in Figure 2, when the MES concentration increased from 20 mM to 50 mM, the separation effect of the acid peak, main peak and base peak of Dupilumab antibody was similar to that when the MES concentration was 30 mM (as shown in Figure 2). Figure 1 ) have comparable separation effects.
[0095] Example 6
[0096] This example studies the effect of different flow rates on the separation of Dupilumab charge isomers.
[0097] The treatment of the test sample is the same as that in Example 1. The only difference between the chromatographic detection conditions and those in Example 1 is the flow rate. Since the recommended flow rate of this chromatographic column is 0.2-0.8 mL / min, the present invention investigates the detection conditions of 0.4 and 0.6 mL / min.
[0098] Test results such as Figure 7 As shown in the figure, when the flow rate increases from 0.4mL / min to 0.6mL / min, the separation effect of the acid-base peaks close to the main peak decreases slightly, but overall remains unchanged and the separation effect can still be achieved.
[0099] Example 7
[0100] This example studies the effect of different salt ion gradients on the separation of Dupilumab charge isomers. The salt ion gradient refers to the ratio of the salt concentration difference of mobile phase B from 7% to 18% to the time used. The salt ion gradient of Example 1 is 1.0 mM / min.
[0101] The treatment of the test sample was the same as in Example 1. The chromatographic conditions were different from those in Example 1 in that the salt ion gradient of mobile phase B was changed, and gradients of 0.6, 0.8, 1.0, and 1.5 mM / min were investigated.
[0102] Test results such as Figure 8 As shown in the figure, as the salt ion gradient increases from 0.6 to 1.5 mM / min, the separation of acid and base peaks decreases, but the separation effect can be achieved. In order to take into account both analysis time and peak resolution, the salt ion gradient of 1.0 mM / min is the best.
[0103] Example 8
[0104] This example investigates the effect of different chromatographic column temperatures on the separation of Dupilumab charge isomers.
[0105] The treatment of the test sample was the same as in Example 1. The chromatographic condition was different from that in Example 1 in terms of column temperature, which was 35°C, 37°C, 40°C and 45°C.
[0106] Test results such as Fig. 9 As shown in the figure, as the column temperature increases from 35°C to 40°C, the peak separation effect of the alkali peak increases slightly. When it is further increased to 45°C, the separation effect is basically the same as that at 35°C, and both can achieve the separation effect. The column temperature has limited improvement on the separation effect of the acid and base peaks, and a column temperature of 40°C is the optimal detection temperature.
[0107] Example 9
[0108] This example is an experiment to test the effect of different acetonitrile concentrations on the separation of Dupilumab charge isomers.
[0109] The only difference from Example 1 is the ratio of acetonitrile added to mobile phase A and mobile phase B. The effects of 0%, 2%, and 5% acetonitrile concentrations (volume percentage) on the separation results were investigated. The detection spectrum is shown in FIG. Fig.10 As shown in Table 5, the analysis results can meet the experimental requirements and the detection of process samples without adding acetonitrile, but after adding 5% volume of acetonitrile, the separation degree of the detection results can be significantly improved.
[0110] Table 5
[0111] Acetonitrile concentration (volume percentage) Separation degree of acid peak A1 and main peak M Acid peak A1 peak-to-valley ratio 0% 0.58 1.25 2% 0.62 1.29 5% 0.89 1.45
[0112] The peak-to-valley ratio of the acid peak A1 = the peak height of the A1 peak / the valley height adjacent to the main peak.
[0113] Example 10
[0114] This example verifies the repeatability of the detection method.
[0115] The treatment of the test sample was the same as in Example 1, and the chromatographic detection conditions were set to mobile phases with a concentration of 30 mM MES and a concentration of 20 mM MES, and other detection conditions remained unchanged. 8 test samples were prepared, and the main peak retention time and the changes in the contents of acidic, neutral and basic charge isomers were compared after detection. The results are shown in Tables 6 and 7, which reflect the repeatability of the detection method with a 30 mM MES mobile phase and a 20 mM MES mobile phase, and the former has better repeatability.
[0116] Table 6. 20 mM MES + 5% acetonitrile as mobile phase
[0117] sample Main peak retention time / min Acid peak content% Main peak content% Alkali peak content% 1 32.186 31.062 61.105 7.833 2 32.238 30.309 61.512 8.179 3 32.222 31.193 61.173 7.634 4 31.955 31.199 61.142 7.659 5 31.984 30.969 61.403 7.728 6 32.039 31.221 61.067 7.712 7 31.968 31.326 61.065 7.609 8 31.947 31.296 61.978 7.726 RSD value 0.39% 1.08% 0.30% 2.21%
[0118] Table 7. 30 mM MES + 5% acetonitrile as mobile phase
[0119]
[0120]
[0121] Embodiment 11
[0122] This example verifies the specificity of the detection method. During the expression of monoclonal antibodies, most of the lysine at the C-terminus of the heavy chain will be removed by carboxypeptidases in the cells, but there is a small amount of lysine residue, which increases the basic charge isomers of the antibody. In other words, the lysine residue at the C-terminus of the heavy chain of the antibody is one of the causes of the basic charge isomers. Therefore, the specificity is verified by detecting the sample after treating Dupilumab monoclonal antibody with carboxypeptidase B.
[0123] Treatment of test sample 2: Take 5 μL of Dupilumab monoclonal antibody (batch number 9L003K), add 295 μL of pH 7.0, 25 mM Tris solution, mix well, and obtain a Dupilumab sample with a concentration of 2.5 mg / mL.
[0124] Sample treatment for Dupilumab monoclonal antibody carboxypeptidase B digestion: Take 150 μL of the above test solution, add 4 μL of carboxypeptidase B solution, and mix well.
[0125] Dupilumab test sample 2 and the enzyme-digested sample were incubated at 37°C for 60 minutes at the same time. The blank solution was a Tris solution with a pH of 7.0 and a concentration of 25 mM.
[0126] The detection chromatographic conditions are the same as those in Table 1. The detection results are as follows: Fig.11 As shown in the figure, compared with the results of digestion with and without carboxypeptidase B, after digestion of test sample 2, the corresponding alkaline peak becomes lower, as shown by the arrow, which is in line with theoretical expectations, indicating that the detection method can effectively separate a small amount of alkaline charge isomers caused by the C-terminal lysine residues of the heavy chain, and compared with the chromatogram of the blank solution, there is no interfering peak at the peak position of the test sample, indicating that this method can be used exclusively for the detection of Dupilumab antibodies.
[0127] Example 12
[0128] This example verifies the linearity of the detection method.
[0129] The treatment and detection conditions of the test sample were the same as those in Example 1. The linearity of the test sample in the range of 25-75 μg was investigated, and three test sample solutions were prepared respectively. Each test sample was measured once at injection volumes of 10 μL, 15 μL, 20 μL, 25 μL, and 30 μL. The average peak areas of acidic, neutral, and basic isomers with different injection volumes were calculated in units of mAU·s. The injection volume of the test sample was used as the abscissa and the average peak area was used as the ordinate. Linear regression was performed on the acidic charge variant, the neutral charge variant, and the basic charge isomer, respectively. The linear correlation coefficient R was obtained based on the regression curve. 2 The specific peak area and correlation coefficient statistics are shown in Table 8, and the regression curve is shown in Fig.12As shown in the figure, it is shown that using this detection method, the linear regression coefficient R of each charge variant is within the range of 25-75μg. 2 All were within the acceptable range of >0.99.
[0130] Table 8
[0131] Injection volume Acidic peak area Neutral peak area Basic peak area 25 μg 1419.014 2838.076 344.150 37.5 μg 2132.289 4266.835 496.096 50μg 2816.487 5690.367 648.115 62.5 μg 3464.802 7130.874 803.470 75 μg 4140.146 8520.819 939.448 <![CDATA[R 2 ]]> 0.9997 1 0.9995
[0132] Embodiment 13
[0133] This example verifies the accuracy of the detection method.
[0134] The treatment and detection conditions of the test sample were the same as those in Example 1. Three test sample solutions were prepared respectively, and each test sample solution was measured once at an injection volume of 12 μL and 18 μL, corresponding to injection volumes of 30 μg and 45 μg, respectively. The peak areas were substituted into the regression equation obtained by linear verification, and the peak areas of acidic, neutral and basic charge isomers were calculated respectively, and the corresponding injection volumes were calculated by dividing the measured injection volume by the theoretical injection volume to obtain the recovery rate (%). The statistical results are shown in Table 9. The recovery rates of all components under each injection volume condition were within the acceptable range of 90%-110%.
[0135] Table 9
[0136]
[0137] Embodiment 14
[0138] In this example, the charge heterogeneity of Nivolumab was analyzed using the same detection conditions to test the versatility of the method.
[0139] Treatment of test sample 3: Take 25 μL of Nivolumab monoclonal antibody (batch number ABR1014), add it to 75 μL of ultrapure water, mix well, and prepare a 2.5 mg / mL test sample 3 solution.
[0140] Separation was performed according to the detection conditions of Example 1, and the results were as follows Fig.13 As shown in the figure, it can be seen that the acidic, neutral and basic charge isomers of IgG4 Nivolumab can be effectively separated using the same detection conditions, and compared with the detection results of Nivolumab monoclonal antibody mentioned in the application data of Thermofisher's weak cation chromatography column (Propac Elite WCX), as shown in the figure. Fig.14 As shown, the method described in the present invention has a better separation effect on Nivolumab antibodies, indicating that the method described in the present invention is universal in the charge heterogeneity analysis of IgG4 antibodies.
[0141] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. An ion exchange chromatography method for detecting charge heterogeneity of IgG4 monoclonal antibodies, characterized in that: The detection conditions include: using a strong cationic chromatographic column with a sulfonic acid functional group and gradient elution with mobile phase A and mobile phase B; The mobile phase A is: MES and its salt buffer solution, the mobile phase A contains 0-10% by volume acetonitrile; The mobile phase B is: MES and its salt buffer solution; the mobile phase B contains acetonitrile with a volume percentage of 0-10%; the mobile phase B contains NaCl; The salt is a sodium salt; The elution gradient is: or 。 2. The method according to claim 1, characterized in that The strong cation chromatographic column is YMC BioPro IEXSF or Thermo MAbPac SCX-10.
3. The method according to claim 1, characterized in that The method further comprises: the mobile phase A or the mobile phase B contains 5% by volume of acetonitrile.
4. The method according to claim 1, characterized in that: The mobile phase A has a pH of 5.7-6.
2.
5. The method according to claim 4, characterized in that The mobile phase A has a pH of 5.8-6.
1.
6. The method according to claim 4, characterized in that The mobile phase A has a pH of 6.
0.
7. The method according to claim 1, characterized in that The mobile phase A is a 10-50 mM MES and salt buffer solution with 5% volume of acetonitrile added thereto.
8. The method according to claim 7, characterized in that The mobile phase A is a 20-50 mM MES and salt buffer solution with 5% volume of acetonitrile added thereto.
9. The method according to claim 7, characterized in that: The mobile phase A is 30 mM MES and its salt buffer solution added with 5% volume of acetonitrile.
10. The method according to claim 7, characterized in that The mobile phase A is a 30 mM MES and salt buffer solution with 5% acetonitrile added thereto, pH 6.
0.
11. The method according to claim 1, characterized in that: The mobile phase B uses the mobile phase A as a base solution and adds a 0.1M-1M sodium salt solution.
12. The method according to claim 11, characterized in that The mobile phase B is based on the mobile phase A and is supplemented with 0.5 M sodium chloride solution.
13. The method according to claim 11, characterized in that The mobile phase B is: 30 mM MES, 0.5 M NaCl, pH 6.0, 5% volume acetonitrile.
14. The method according to claim 1, characterized in that The method further comprises a mobile phase flow rate of 0.2-1.5 mL / min.
15. The method according to claim 14, characterized in that The method further comprises a mobile phase flow rate of 0.4-0.6 mL / min.
16. The method according to claim 14, characterized in that The method further includes a mobile phase flow rate of 0.4 mL / min.
17. The method according to claim 1, characterized in that The method further comprises that the chromatographic column temperature is 20-50°C during detection.
18. The method according to claim 17, characterized in that The method further comprises that the chromatographic column temperature is 40°C during detection.
19. The method according to claim 1, characterized in that The method further comprises adopting an ultraviolet detector with a detection wavelength of 280 nm and an injection volume of 5-100 μg.
20. The method according to claim 19, characterized in that The method further comprises adopting an ultraviolet detector with a detection wavelength of 280 nm and an injection volume of 25-75 μg.
21. The method according to claim 1, characterized in that The method further includes processing of the test sample: taking IgG4 monoclonal antibodies and biosimilars thereof, adding ultrapure water, and mixing to obtain a sample to be tested with a concentration of 2.5 mg / mL.
22. The method according to claim 1, characterized in that The IgG4 monoclonal antibody is Dupilumab and its biosimilars, or Nivolumab and its biosimilars.
23. The method according to any one of claims 1 to 22, characterized in that: The method further includes that the efficient detection conditions of the charge heterogeneity of Dupilumab and its biosimilars or Nivolumab and its biosimilars are as follows: Chromatographic column: YMC BioPro IEX SF or Thermo MAbPac SCX-10 Mobile phase: A: 30 mM MES, pH 6.0, 5% acetonitrile; B: 30 mM MES, 0.5 M NaCl, pH 6.0, 5% acetonitrile Column temperature: 40°C Detection wavelength: 280nm Injection volume: 25 μg Flow rate: 0.4mL / min Mobile phase gradient: 。 24. The method according to claim 23, characterized in that The method comprises: Preparation of the test sample: Take Dupilumab or Nivolumab, add ultrapure water, mix well, and obtain a test sample with a concentration of 2.5 mg / mL.
